ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
JP
/
EN
メニューアイコン
Press
Craif Reports One Stage 0 Lung Cancer Found and Surgically Removed in a 100 Person Urine Screening Study in Hokkaido
2025.06.16

Single case from an exploratory prospective observational study run with Professor Tatsuya Kato of Hokkaido University Hospital, presented at the 42nd Annual Meeting of the Japanese Association for Chest Surgery.

TOKYO, June 15, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, presented results from an exploratory prospective observational study of lung cancer screening at the 42nd Annual Meeting of the Japanese Association for Chest Surgery, held May 15 and 16, 2025 at Grand Nikko Tokyo Daiba.

The study was run with Professor Tatsuya Kato of Hokkaido University Hospital and colleagues. The presentation was titled “Verification of the effectiveness of lung cancer screening using miSignal in Hokkaido.”

In the study's follow-up, one participant whose miSignal result indicated a high risk of lung cancer went on to confirmatory examination, and a lesion suspected of being lung cancer was found. Surgery removed the lesion, and the outcome was described as a complete cure of Stage 0 lung cancer, specifically adenocarcinoma in situ.

This is a single case. The number of the 100 participants classified as high risk by miSignal Scan, the number who went on to imaging, and the lung cancer diagnosis rate the study was designed to measure have not been reported, nor have sensitivity, specificity or other performance metrics. The work was presented at a scientific meeting and has not been published in a peer-reviewed journal.

Background and objectives

Craif works toward a society where people live out their natural lifespan by shifting the center of medicine from treatment to prevention and by supporting the early detection and early treatment of cancer and other diseases. In Japan, one person in two develops cancer and one in three dies of it, while cancer screening participation remains at roughly 40 percent, low by international standards.

Hokkaido is a particular case. The prefecture's geography and shortages of facilities and staff limit medical resources, and screening rates for every cancer site are substantially lower than in other prefectures. Low screening rates make early detection harder, which raises the risk of advanced disease and higher healthcare costs.

In 2023, Craif helped establish CRUSH-Cancer, a consortium for the early detection and early treatment of cancer. As part of that work, Craif ran this prospective observational study of lung cancer using the urine-based cancer risk test miSignal Scan in the town of Iwanai, Hokkaido, where the cancer screening rate is approximately 6 percent, and supported resident awareness activities through cancer education events. Higher screening participation is generally understood to help find cancer earlier, and Craif intends to keep addressing Hokkaido's low screening rates, which follow in part from geography, with a test that is accurate, simple and possible to use at home.

Sources: the roughly 40 percent national screening rate, National Cancer Center Japan, Cancer Control Information Center; the prefecture-level comparison, National Cancer Center Japan Cancer Information Service, Cancer Statistics, Comprehensive Survey of Living Conditions, screening rates by prefecture, 2019; the approximately 6 percent figure for Iwanai, FY2022 Report on Regional Public Health Services and Health Promotion Services, Ministry of Health, Labour and Welfare.

The study

Craif provided 100 miSignal Scan kits at no charge to people considered to be at high risk of lung cancer. Participants whose results came back high risk were followed up, and the study was designed to evaluate the rate at which lung cancer was diagnosed in that group. Craif and the Hokkaido University Hospital team also intend to follow participants over several years to estimate lung cancer incidence, its effect on prognosis, and the factors related to both.

In that follow-up, one participant whose result was high risk underwent confirmatory examination; a lesion suspected of being lung cancer was found, and surgery removed a Stage 0 lung cancer, adenocarcinoma in situ.

Study details:

  • Objective: to conduct lung cancer surveillance with miSignal Scan in a population at high risk of lung cancer, evaluate the diagnosis rate, and estimate incidence, the effect on prognosis, and related factors from follow-up
  • Type: exploratory prospective observational study
  • Participants: 100 residents of the towns of Iwanai and Yoichi, Hokkaido
  • Period: through March 2025
  • Investigators: Professor Tatsuya Kato, Hokkaido University Hospital, and colleagues, with Craif

A prospective observational study collects data by observing health status and disease occurrence in a defined population, without intervening with treatment or instruction, other than tests carried out as they would be in ordinary care.

Limitations

Adenocarcinoma in situ is non-invasive and is classified as Stage 0. The study did not compare miSignal Scan with low-dose CT screening, and a single case does not establish the performance of a screening test.

About the 42nd Annual Meeting of the Japanese Association for Chest Surgery

About miSignal Scan

miSignal Scan is a urine based cancer risk test built on microRNA, which plays an important role in the onset, progression and metastasis of cancer. It involves no pain. A user collects a urine sample at home or at a participating medical institution. The test currently covers up to seven cancer types: colorectal, lung, gastric, breast, pancreatic, esophageal and ovarian cancer.

More information: https://misignal.jp/

The miSignal series is not a medical device. It estimates risk by statistical calculation from analyzed data, it does not substitute for a physician's diagnosis of whether cancer is present, and a low risk result does not mean that cancer is absent or that cancer will not develop in the future.

About CRUSH-Cancer

CRUSH-Cancer, short for Cooperative Research group for Urinary miRNA-SCREENING-Hokkaido-Cancer, is a consortium for the early detection and early treatment of cancer, formed by five organizations with medical technology cooperation from several additional institutions. Its purpose is to test the medical and social usefulness of the urine based cancer risk test miSignal.

Member organizations:

  • Craif Inc. (Bunkyo-ku, Tokyo; CEO: Ryuichi Onose)
  • Satsudora Holdings Co., Ltd. (Sapporo, Hokkaido; President and CEO: Hiroki Tomiyama)
  • Hokuto Hospital, Social Medical Corporation Hokuto (Obihiro, Hokkaido; Chairman: Hajime Kamata)
  • Moriyama Hospital, Social Medical Corporation Genseikai (Asahikawa, Hokkaido; Chairman: Ryo Moriyama)
  • Seiwa Memorial Hospital, Medical Corporation Seiwakai (Sapporo, Hokkaido; Chairman: Masato Kawakami)

Medical technology cooperation:

  • Professor Mikihiro Fujiya, Division of Gastroenterology and Endoscopy, Department of Internal Medicine, Asahikawa Medical University
  • Professor Satoshi Hirano, Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine
  • Professor Hidemichi Watari, Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine
  • Professor Tatsuya Kato, Division of Thoracic Surgery, Department of Surgery, Hokkaido University Graduate School of Medicine

About Craif

Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.

Media contact

press_us@craif.com